Abstracts tagged "anti-TNF therapy"

Abstract Number: 2060 • 2015 ACR/ARHP Annual Meeting
Microscopic Bowel Inflammation in Spondyloarthritis As a Baseline Predictor of Anti-TNF Response
Heleen Cypers, Gaëlle Varkas, Filip van Den Bosch and Dirk Elewaut, Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium
· Background/Purpose: Microscopic bowel inflammation without associated gastro-intestinal symptoms is present in up to 50% of spondyloarthritis (SpA) patients. Two types of inflammation are distinguished based…
Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 1313 • 2015 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Trine David Jensen², Pernille Bach Mortensen², Lars Hyldstrup², Pernille Boyesen³, Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Hanne Lindegaard¹, Uta Engling Poulsen¹, Annette Hansen¹, Annette Schlemmer¹, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹ and Merete Lund Hetland¹, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and loss of periarticular bone mass. Thus hand bone loss (HBL) has been proposed as…
Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
John Stack¹, Claire-Louise Murphy², Clara Bannon¹, Eithne Murphy¹, Trevor Duffy¹ and Maurice Barry¹, ¹Rheumatology, Connolly Hospital Blanchardstown, Dublin, Ireland, ²Rheumatology, Connolly Hospital Blanchardstow, Dublin, Ireland
Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…
Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa¹, Emilio Martín-Mola¹, Daniel Seoane-Mato³ and Juan D. Cañete⁴, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 1331 • 2015 ACR/ARHP Annual Meeting
Change in MRI in Patients with Spondyloarthritis Treated with Anti-TNF Agents : Systematic Review of the Literature
Gisèle KHOURY¹, BG Combe² and Cédric Lukas³, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Lapeyronie, Montpellier, France, ³Hopital Lapeyronie, Montpellier, France
Background/Purpose: The follow-up of axial spondyloarthritis (SpA) remains difficult in clinical practice, mainly based on patient-reported outcomes, whereas objective parameters in disease monitoring are often…
Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Vibeke Strand¹, M. Elaine Husni², Zheng-Yi Zhou³, James Signorovitch³, Jenny Griffith⁴, Yichen Zhong³ and Arijit Ganguli⁴, ¹Stanford University, Palo Alto, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
Abstract Number: 616 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Exacerbation of Interstitial Lung Disease (ILD) after Administration of Biologic Dmards in RA Patients with Pre-Existing ILD
Tamao Nakashita¹, Akira Dibatake², Kotaro Matsumoto³, Yoto Hamada⁴ and Shinji Motojima⁵, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan, ³Department of Rheumatology and Allergy, Kameda Medical Center, kamogawa, Japan, ⁴Department of Rheumatology and Allergy, Kameda Medical Center, Kamogwa, Japan, ⁵Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of death…
Abstract Number: 1351 • 2015 ACR/ARHP Annual Meeting
Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Juliana Brunelli¹, Karina Bonfiglioli^2,3, Clovis A Silva⁴, Katia T. Kozu⁵, Cláudia Goldenstein-Schainberg⁶, Eloisa Bonfá¹ and Nadia E Aikawa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁶Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: We have demonstrated previously that latent tuberculosis infection (LTBI) screening is effective in adult rheumatoid arthritis (RA) patients prior to anti-TNF treatment. One study…
Abstract Number: 2149 • 2015 ACR/ARHP Annual Meeting
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Jorge Gratacos-Masmitja¹, Caridad Pontes², Ferran Torres³, Xavier Juanola⁴, Antoni Vallano⁵, TC Salman-Monte⁶, Francisco J. Blanco⁷, Agusti Sellas-Fernandez⁸, Raimon Sanmarti⁹, Gonzalo Calvo¹⁰, Teresa Clavaguera¹¹, Raul Veroz Gonzalez¹², Juan Carlos Torre Alonso¹³, Jesus Sanz¹⁴, Cristina Avendaño¹⁵, Carlos Rodriguez-Lozano¹⁶, Luis Francisco Linares¹⁷, Ana Urruticoechea¹⁸, Eduardo Collantes-Estévez¹⁹, Rosa Morla Novell²⁰, Delia Reina²¹, Eduardo Cuende²², Pedro Zarco²³, Cruz Fernández- Espartero²⁴, Rosario Garcia-Vicuña²⁵, Carlos Alberto Montilla Morales²⁶, Eugenio De Miguel²⁷, Roser Vives² and Mireia Moreno²⁸, ¹Rheumatology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ²Clinical Pharmacology, Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain, ³Biostatistics and Data Management Platform, IDIBAPS - Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, ⁷Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Spain, ¹¹CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ¹²Hospital de Mérida, Mérida, Spain, ¹³Perez de la Sala 33, 3oA., H. Monte Naranco, Oviedo, Spain, ¹⁴Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁵Hospital Puerta de Hierro - Majadahonda, Madrid, Spain, ¹⁶Hospital Ubniversitario Dr. Negrin, Las Palmas de Gran Canaria, Spain, ¹⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ¹⁸Hospital Can Misses, Ibiza, Spain, ¹⁹IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, ²⁰Rheumatology UNit., Hospital Sta Tecla, Tarragona, Spain, ²¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ²³H Fundación Alcorcón, Alcorcón, Spain, ²⁴Rheumatology, Hospital La Zarzuela, Madrid, Spain, ²⁵Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²⁶Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ²⁷Rheumatology, University Hospital La Paz, Madrid, Spain, ²⁸Hospital de Sabadell - Institut Universitari Parc Taulí, Sabadell, Spain
Background/Purpose: Tumour Necrosis Factor alpha inhibitors (TNFi) have proven to be effective in the treatment of with spondyloarthropaties. There is rationale to support that in…
Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting
Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
Louis Bessette¹, Proton Rahman², Denis Choquette³, John Kelsall⁴, Maqbool Sheriff⁵, Emmanouil Rampakakis⁶, Eliofotisti Psaradellis⁷, Allen J Lehman⁸, Karina Maslova⁸, Francois Nantel^9,10, Brendan Osborne¹¹ and Cathy Tkaczyk¹¹, ¹Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…
Abstract Number: 618 • 2015 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score in Methotrexate Incomplete Responders Predicts Clinical Responses to Non-Biological Versus Biological Therapy in Early RA
Karen Hambardzumyan¹, Rebecca J. Bolce², Saedis Saevarsdottir³, Kristina Forslind^4,5, Johan A Karlsson⁶ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ⁵Departments of Rheumatology, Helsingborgs Hospital and University of Lund, Helsingborg and Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: The Swedish Farmacotherapy (SWEFOT) trial and other trials in rheumatoid arthritis (RA) demonstrated that in MTX incomplete responder patients (MTX-IR) the addition of anti-TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].